1. Arti V. Shinde, Claudio Humeres, and Nikolaos G. Frangogiannis (2017) The role of α-smooth muscle actin in fibroblast-mediated matrix contraction and remodeling. Biochim Biophys Acta Mol Basis Dis. 1863: 298–309.
2. Xiaoyi Li, Lixin Zhu, Beibei Wang, Meifei Yuan, and Ruixin Zhu (2017) Drugs and targets in fibrosis. Front Pharmacol. 8: 855.
3. Saleh Yazdani, Ruchi Bansal, and Jai Prakash (2017) Drug targeting to myofibroblasts: Implications for fibrosis and cancer. Adv Drug Deliv Rev. 121: 101–116.
4. Rivka C. Stone, Irena Pastar, Nkemcho Ojeh, Vivien Chen, Sophia Liu, Karen I. Garzon, and Marjana Tomic-Canic (2016) Epithelial-mesenchymal transition in tissue repair and fibrosis. Cell Tissue Res. 365: 495–506.
5. Tsutomu Inoue, Akihiro Umezawa, Tsuneo Takenaka, Hiromichi Suzuki, and Hirokazu Okada (2015) The contribution of epithelial-mesenchymal transition to renal fibrosis differs among kidney disease models. Kidney Int. 87: 233–238.
6. John Holian, Weier Qi, Darren J. Kelly, Yuan Zhang, Ellein Mreich, Carol A. Pollock, and Xin-Ming Chen (2008) Role of kruppel-like factor 6 in transforming growth factor-β1-induced epithelialmesenchymal transition of proximal tubule cells. Am J Physiol Renal Physiol. 295: 1388–1396.
7. Hui Y. Lan (2003) Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells. Curr Opin Nephrol Hypertens. 12: 25–29.
8. Maki Shimizu, Shuji Kondo, Maki Urushihara, Masanori Takamatsu, Katsuyoshi Kanemoto, Michio Nagata, and Shoji Kagami (2006) Role of integrin-linked kinase in epithelial-mesenchymal transition in crescent formation of experimental glomerulonephritis. Nephrol Dial Transplant. 21: 2380–2390.
9. Yogesh M. Scindia, Umesh S. Deshmukh, and Harini Bagavant (2010) Mesangial pathology in glomerular disease: targets for therapeutic intervention. Adv Drug Deliv Rev. 62: 1337–1343.
10. Maria Fragiadaki, and Roger M. Mason (2011) Epithelial-mesenchymal transition in renal fibrosis – evidence for and against. Int J Exp Pathol. 92: 143–150.
11. Motoko Yanagita, Hidenori Arai, Toru Nakano, Kazumasa Ohashi, Kensaku Mizuno, Atsushi Fukatsu, Toshio Doi, and Toru Kita (2001) Gas6 induces mesangial cell proliferation via latent transcription factor STAT3. J Biol Chem. 276: 42364–42369.
12. Motoko Yanagita, Hidenori Arai, Kenji Ishii, Toru Nakano, Kazumasa Ohashi, Kensaku Mizuno, Brian Varnum, Atsushi Fukatsu, Toshio Doi, and Toru Kita (2001) Gas6 regulates mesangial cell proliferation through Axl in experimental glomerulonephritis. Am J Pathol. 158: 1423–1432.
13. Motoko Yanagita (2004) The role of the vitamin K-dependent growth factor Gas6 in glomerular pathophysiology. Curr Opin Nephrol Hypertens. 13: 465–470.
14. Motoko Yanagita (2004) Gas6, warfarin, and kidney diseases. Clin Exp Nephrol. 8: 304–309.
15. Anette Fiebeler, Joon-Keun Park, Dominik N. Muller, Carsten Lindschau, Michael Mengel, Saskia Merkel, Bernhard Banas, Friedrich C. Luft, and Hermann Haller (2004) Growth arrest specific protein 6/Axl signaling in human inflammatory renal diseases. Am J Kidney Dis. 43: 286–295.
16. Iris J. Lee, Brendan Hilliard, Abhishek Swami, John C. Madara, Swati Rao, Tapan Patel, John P. Gaughan, Jean Lee, Crystal A. Gadegbeku, Eric T. Choi, and Philip L. Cohen. (2012) Growth arrest-specific gene 6 (Gas6) levels are elevated in patients with chronic renal failure. Nephrol Dial Transplant. 27: 4166–4172.
17. Jane Antony, and Ruby Yun-Ju Huang (2017) Axl-driven EMT state as a targetable conduit in cancer. Cancer Res. 77: 3725–3732.
18. Milena S. Espindola, David M. Habiel, Rohan Narayanan, Isabelle Jones, Ana L. Coelho, Lynne A. Murray, Dianhua Jiang, Paul W. Noble, and Cory M. Hogaboam (2018) Targeting of TAM receptors ameliorates fibrotic mechanisms in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 197: 1443–1456.
19. Atsuo Kurata, Yukako Tachibana, Tadakatsu Takahashi, and Naoshi Horiba. (2020) Novel Axl-specific inhibitor ameliorates kidney dysfunction through the inhibition of epithelial-to-mesenchymal transition of renal tubular cells. PLoS One. 15: e0232055.
20. Larissa Knüppel, Yoshihiro Ishikawa, Michaela Aichler, Katharina Heinzelmann, Rudolf Hatz, Jürgen Behr, Axel Walch, Hans Peter Bächinger, Oliver Eickelberg, and Claudia A. Staab-Weijnitz (2017) A novel antifibrotic mechanism of nintedanib and pirfenidone. Inhibition of collagen fibril assembly. Am J Respir Cell Mol Biol. 57: 77–90.
21. Robert G. Hart, Lesly A. Pearce, Richard W. Asinger, and Charles A. Herzog (2011) Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol. 6: 2599–2604.
22. Christine Perret-Guillaume, and Denis G. Wahl (2004) Low-dose warfarin in atrial fibrillation leads to more thromboembolic events without reducing major bleeding when compared to adjusted-dose: a meta-analysis. Thromb Haemost. 91: 394–402.
23. Simone Rost, Andreas Fregin, Vytautas Ivaskevicius, Ernst Conzelmann, Konstanze Hörtnagel, Hans-Joachim Pelz, Knut Lappegard, Erhard Seifried, Inge Scharrer, Edward G. D. Tuddenham, Clemens R. Müller, Tim M. Strom, and Johannes Oldenburg (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 427: 537–541.
24. Yuka Sakaguchi, Sachiko Suga, Keiyu Oshida, Keiko Miyamoto-Kuramitsu, Kohei Ueda, and Yohei Miyamoto (2008) Anticoagulant effect of sodium dehydroacetate (DHA-S) in rats. J Appl Toxicol. 28: 524–529.
25. Sangwook Wu, Xuejie Chen, Da-Yun Jin, Darrel W. Stafford, Lee G. Pedersen, and Jian-Ke Tie (2018) Warfarin and vitamin K epoxide reductase: a molecular accounting for observed inhibition. Blood. 132: 647–657.
26. Carville G. Bevans, Christoph Krettler, Christoph Reinhart, Hélène Tran, Katja Koßmann, Matthias Watzka, and Johannes Oldenburg (2013) Determination of the warfarin inhibition constant Ki for vitamin K 2, 3-epoxide reductase complex subunit-1 (VKORC1) using an in vitro DTT-driven assay. Biochim Biophys Acta. 1830: 4202–4210.
27. Nicholas Au, and Allan E. Rettie. (2008) Pharmacogenomics of 4- hydroxycoumarin anticoagulants. Drug Metab Rev. 40: 355–375.
28. Henk H. Thijssen. (1987) Warfarin resistance. Vitamin K epoxide reductase of Scottish resistance genes is not irreversibly blocked by warfarin. Biochem Pharmacol. 36: 2753–2757.
29. Christina R. Wilson, John-Michael Sauer, Gary P. Carlson, Reidar Wallin, Michael P. Ward, and Stephen B. Hooser (2003) Species comparison of vitamin K1 2, 3- epoxide reductase activity in vitro: kinetics and warfarin inhibition. Toxicology. 189: 191–198.
30. Louise A. Begent, Anthony P. Hill, Glyn B. Steventon, Andrew J. Hutt, Christopher J. Pallister, and David C. Cowell (2001) Characterization and purification of the vitamin K1 2, 3 epoxide reductases system from rat liver. J Pharm Pharmacol. 53: 481–486.
31. Katrin J. Czogalla, Arijit Biswas, Ann-Christin Wendeln, Philipp Westhofen, Clemens R. Müller, Matthias Watzka, and Johannes Oldenburg (2013) Human VKORC1 mutations cause variable degrees of 4-hydroxycoumarin resistance and affect putative warfarin binding interfaces. Blood. 122: 2743–2750.
32. Katrin J. Czogalla, Arijit Biswas, Klara Höning, Veit Hornung, Kerstin Liphardt, Matthias Watzka, and Johannes Oldenburg (2017) Warfarin and vitamin K compete for binding to Phe55 in human VKOR. Nat Struct Mol Biol. 24: 77–85.
33. Markus Gebauer (2007) Synthesis and structure-activity relationships of novel warfarin derivatives. Bioorg Med Chem. 15: 2414–2420.
34. Susan E. Hazelett, and Peter C. Preusch (1988) Tissue distribution and warfarin sensitivity of vitamin K epoxide reductase. Biochem Pharmacol. 37: 929–934.
35. Tao Li, Chun-Yun Chang, Da-Yun Jin, Pen-Jen Lin, Anastasia Khvorova, and Darrel W. Stafford (2004) Identification of the gene for vitamin K epoxide reductase. Nature. 427: 541–544.
36. Weikai Li, Sol Schulman, Rachel J. Dutton, Dana Boyd, Jon Beckwith, and Tom A. Rapoport (2010) Structure of a bacterial homolog of vitamin K epoxide reductase. Nature. 463: 507–512.
37. Philipp Westhofen, Matthias Watzka, Milka Marinova, Moritz Hass, Gregor Kirfel, Jens Müller, Carville G. Bevans, Clemens R. Müller, and Johannes Oldenburg (2011) Human vitamin K1 2, 3-epoxide reductase complex subunit 1-like 1 (VKORC1L1) mediates vitamin K-dependent intracellular antioxidant function. J Biol Chem. 286: 15085–15094.
38. Abdessalem Hammed, Benjamin Matagrin, Gabriele Spohn, Caroline Prouillac, Etienne Benoit, and Virginie Lattard (2013) VKORC1L1, an enzyme rescuing the vitamin K 2, 3-epoxide reductase activity in some extrahepatic tissues during anticoagulation therapy. J Biol Chem. 288: 28733–28742.
39. Jahmar Thompson, Sanford Markey, and Paul V. Fennessey (1975) Gas- chromatographic/mass-spectrometric identification and quantitation of tetronic and deoxytetronic acids in urine from normal adults and neonates. Clin Chem. 21: 1892–1898.
40. Christian Fleck, and Helmut Bräunlich (1990) Factors determining the relationship between renal and hepatic excretion of xenobiotics. Arzneimittelforschung. 40: 942–946.
41. Gang Luo, Stephen Johnson, Mei-Mann Hsueh, Joanna Zheng, Hong Cai, Baomin Xin, Saeho Chong, Kan He, and Timothy W. Harper (2009) In silico prediction of biliary excretion of drugs in rats based on physicochemical properties. Drug Metab Dispos. 38: 422–430.
42. Mike Ufer (2005) Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 44: 1227– 1246.
43. Henk H. Thijssen, Catharina A. Janssen, and M. J. Drittij-Reijnders (1986) The effect of S-warfarin administration on vitamin K1 2, 3-epoxide reductase activity in liver, kidney and testis of the rat. Biochem Pharmacol. 35: 3277–3282.
44. Thorir D. Bjornsson (1979) Use of serum creatinine concentrations to determine renal function. Clin Pharmacokinet. 4: 200–222.
45. Inger M. Darling, and Marilyn E. Morris (1991) Evaluation of “true” creatinine clearance in rats reveals extensive renal secretion. Pharm Res. 8: 1318–1322.
46. M. Robertshaw, Kar N. Lai, and Ramyasuda Swaminathan (1989) Prediction of creatinine clearance from plasma creatinine: comparison of five formulae. Br J Clin Pharmacol. 28: 275–280.
47. Wilfred Lieberthal, Veronica Triaca, and Jerrold S. Levine (1996) Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol. 270: 700–708.
48. Satoru Sugiyama, Mika Hayakawa, Tomoko Kato, Yoshihiro Hanaki, Kazuyuki, Shimizu, and Takayuki Ozawa (1989) Adverse effects of anti-tumor drug, cisplatin, on rat kidney mitochondria: disturbances in glutathione peroxidase activity. Biochem Biophys Res Commun. 159: 1121–1127.
49. Sarah Faubel, Eli C. Lewis, Leonid Reznikov, Danica Ljubanovic, Thomas S. Hoke, Hilary Somerset, Dong-Jin Oh, Lawrence Lu, Christina L. Klein, Charles A. Dinarello, and Charles L. Edelstein (2007) Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther. 322: 8–15.
50. Ganesan Ramesh, and Willam B. Reeves (2002) TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest. 110: 835–842.
51. James E. McDuffie, Marciano Sablad, JingY. Ma, and Sandra Snook (2010) Urinary parameters predictive of cisplatin-induced acute renal injury in dogs. Cytokine. 52: 156–162.
52. Yoshiko Kawai, Tomohiko Satoh, Daisuke Hibi, Yukihiro Ohno, Yuka Kohda, Katsuyuki Miura, and Munekazu Gemba (2009) The effect of antioxidant on development of fibrosis by cisplatin in rats. J Pharmacol Sci. 111: 433–439.
53. Agnès Fourcot, Dominique Couchie, Marie-Noele Chobert, Elie-Serge Zafrani, Philippe Mavier, Yannick Laperche, and Arthur Brouillet (2011) Gas6 deficiency prevents liver inflammation, steatohepatitis, and fibrosis in mice. Am J Physiol Gastrointest Liver Physiol. 300: 1043–1053.
54. Martina Perše, and Željka Večerić-Haler (2018) Cisplatin-induced rodent model of kidney injury: characteristics and challenges. Biomed Res Int. 2018: 1462802.
55. Emi Yamamato, Takeshi Izawa, Osamu Sawamoto, Vetnizah Juniantito, Mitsuru Kuwamura, and Jyoji Yamate (2012) Amelioration of cisplatin-induced rat renal lesions by a cyclooxygenase (COX)-2 selective inhibitor. Exp Toxicol Pathol. 64: 625–631.
56. Peng Zhou, Xun Sun, and Zhirong Zhang (2014) Kidney-targeted drug delivery systems. Acta Pharm Sin B. 4: 37–42.
57. Yusuke Kamiya, Shohei Otsuka, Tomonori Miura, Manae Yoshizawa, Ayane Nakano, Miyu Iwasaki, Yui Kobayashi, Makiko Shimizu, Masato Kitajima, Fumiaki Shono, Kimito Funatsu, and Hiroshi Yamazaki (2020) Physiologically based pharmacokinetic models predicting renal and hepatic concentrations of industrial chemicals after virtual oral doses in rats. Chem Res Toxicol. 33: 1736– 1751.
58. Shona Methven, Mark S. MacGregor, Jamie P. Traynor, Denis St J. O'Reilly, and Christopher J. Deighan (2010) Assessing proteinuria in chronic kidney disease: protein-creatinine ratio versus albumin-creatinine ratio. Nephrol Dial Transplant. 25: 2991–2996.